Novartis CEO's statin? Pfizer's Lipitor

What's a pharma CEO with high cholesterol to do? Take his company's statin, of course. But Novartis chief Daniel Vasella (photo) eschews Lescol in favor of... Pfizer's Lipitor. Vasella tried Lescol. Twice. But side effects pushed him off the drug and onto Lipitor.

As the Wall Street Journal's Health Blog notes, Vasella's experience is just one of the many times Lescol has lost out. Viewed as less potent than other statins, Lescol totes up global sales of less than $1 billion, compared with $10 billion for Lipitor. And both now are losing out to Zocor imitators.

- check out the item from the Health Blog

Related Articles:
Sleep study could boost some statins. Report
Switching to generic statins not so healthy. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.